Abstract:Background: Fine-needle aspiration (FNA) biopsy is typically used in conjunction with cytopathologic evaluation to differentiate between benign and malignant thyroid nodules. Even so, the cytology results for 20-30% of thyroid nodules are indeterminate. This study sought to evaluate the usefulness of next-generation sequencing (NGS)-based multi-gene panel testing for risk stratification and the differentiation of benign from malignant thyroid nodules. Methods: Thyroid nodule samples were obtained from a cohort of 359 patients who underwent FNA. An NGS-based multi-gene panel testing was conducted for these samples, in which single-nucleotide variants (SNVs) and small insertion/deletions (InDels) can be detected in 11 genes and fusion events can be identified in 5 genes. Surgical resection was conducted for 113 patients (113/359), and then histopathology results were obtained. Results: In comparison to cytology alone, the diagnostic sensitivity of NGS combination cytology increased from 0.7245 (95% CI: 0.6289-0.8032) to 0.898 (95% CI: 0.8223-0.9437); the associated AUC was 0.8303 (vs. Cytology AUC: 0.7622, P < 0.001). BRAF V600E was identified in 136 patients, of whom 79 underwent surgery and were diagnosed with papillary thyroid carcinoma (PTC) pathologically. TERT promoter mutations or BRAF / RAS co-mutations with other genes were identified in 5 patients, while 4 patients were diagnosed with malignant thyroid cancer using the pathological method. RAS mutations were identified in 27 patients, while 10 patients underwent surgery, which showed that 3 patients were classified as PTC and 7 cases were benign. In addition, 4 RET fusions, 1 RET activation mutation, and 3 TP53 inactivation mutations were identified in the remaining 8 patients who have not undergone surgery. Negative genetic test results or variants with uncertain significance were identified in 183 patients. Among these patients, 12 malignant thyroid tumors, including 11 PTC and 1 MTC, were diagnosed in 20 patients who received surgery. Conclusion: Thyroid nodules coupled with BRAF V600E , TERT promoter variants, BRAF / RAS co-mutations with other genes, RET fusions, and RET activating mutations were classified as high-risk. Nodules with RAS mutations ( NRAS , KRAS , HRAS ) and TP53 inactivating mutations were considered to be in the intermediate-risk group, while those with non-pathogenic mutations (negative and variants of uncertain significance) were placed in the low-risk group. When combined with cytopathology, NGS increases the sensitivity of diagnosing benign and malignant thyroid nodules, and the reference is useful for patient risk stratification.

Impact of the quality of resected thyroid cancer tissue sample on next‐generation sequencing testing

Diagnostic Performance of Next-Generation Sequencing and Genetic Profiling in Thyroid Nodules from a Single Center in China

Real world data analysis of next-generation sequencing and corresponding clinical characteristics in thyroid tumor

Next-Generation Sequencing Enhances the Diagnosis Efficiency in Thyroid Nodules

Next-Generation-Sequencing on fine needle aspirates in neck recurrence of thyroid cancers

Effective Preparation of FFPE Tissue Samples for Preserving Appropriate Nucleic Acid Quality for Genomic Analysis in Thyroid Carcinoma

Next-Generation sequencing genomic landscape of Chinese thyroid tumors

The value of NGS-based multi-gene testing for differentiation of benign from malignant and risk stratification of thyroid nodules

Clinicopathological analysis of thyroid carcinomas with the RET and NTRK fusion genes: characterization for genetic analysis

Next generation sequence-based targeted somatic mutation analysis in thyroid nodules with pathologically diagnosed as indeterminate cytology

Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules

ThyroSeq overview on indeterminate thyroid nodules: An institutional experience

Next‐generation sequencing in residual liquid‐based cytology specimens for cancer genome analysis

Diagnostic value and lymph node metastasis prediction of a custom‑made panel (thyroline) in thyroid cancer

Clinical utility of the Oncomine Dx Target Test multi‐CDx system and the possibility of utilizing those original sequence data

Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance Cytology

Highly Accurate NGS-based Multi-Gene Testing in the Diagnosis of Thyroid Nodules with Indeterminate Cytology.

Utility of a Multigene Testing for Preoperative Evaluation of Indeterminate Thyroid Nodules: A Prospective Blinded Single Center Study in China

Correlation between gene mutations and clinical characteristics in papillary thyroid cancer: a retrospective analysis of BRAF mutations and RET rearrangements

Clinicopathological Features of CCDC6-RET and NCOA4-RET Fusions in Thyroid Cancer: A Single-center Retrospective Cohort Study in a Chinese Population

Small Multi-Gene DNA Panel Can Aid in Reducing the Surgical Resection Rate and Predicting the Malignancy Risk of Thyroid Nodules